Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Foliglurax in Healthy Men
NCT04002895Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jun 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of foliglurax in Parkinson's disease (PD), sponsored by Lundbeck. Primary endpoints: Total amount of radioactivity excreted at Day 11, Area under the concentration-time curve from time zero to infinity at Day 11 and 3 more. Started Jun 2019; status: completed.
02
Drugs
foliglurax
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04002895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002895.